190 related articles for article (PubMed ID: 37833892)
21. Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease.
Charkhand B; Scantlebury MH; Narita A; Zimran A; Al-Hertani W
Mol Genet Metab Rep; 2019 Sep; 20():100476. PubMed ID: 31467847
[TBL] [Abstract][Full Text] [Related]
22. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
23. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
24. Abdominal lymphadenopathy in children with Gaucher disease: Relation to disease severity and glucosylsphingosine.
Tantawy AAG; Adly AAM; Atif HM; Madkour SS; Salah NY
Pediatr Hematol Oncol; 2022 May; 39(4):304-317. PubMed ID: 34668825
[TBL] [Abstract][Full Text] [Related]
25. Patients with Gaucher disease display systemic oxidative stress dependent on therapy status.
Kartha RV; Terluk MR; Brown R; Travis A; Mishra UR; Rudser K; Lau H; Jarnes JR; Cloyd JC; Weinreb NJ
Mol Genet Metab Rep; 2020 Dec; 25():100667. PubMed ID: 33335836
[TBL] [Abstract][Full Text] [Related]
26. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
27. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
[TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
29. Treatment-naive and post-treatment glucosylsphingosine (lyso-GL1) levels in a cohort of pediatric patients with Gaucher disease.
Rasmussen CA; Quadri A; Vucko E; Kim K; Hickey R; Baker JJ; Charrow J; Prada CE
Mol Genet Metab; 2024 Jan; 141(1):107736. PubMed ID: 38000346
[TBL] [Abstract][Full Text] [Related]
30. Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Rivard GÉ; Auray-Blais C
Bioanalysis; 2022 Feb; 14(4):223-240. PubMed ID: 35118875
[No Abstract] [Full Text] [Related]
31. Soluble mannose receptor: A potential biomarker in Gaucher disease.
Beaton B; Hughes DA
Eur J Haematol; 2024 May; 112(5):794-801. PubMed ID: 38200687
[TBL] [Abstract][Full Text] [Related]
32. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.
Rolfs A; Giese AK; Grittner U; Mascher D; Elstein D; Zimran A; Böttcher T; Lukas J; Hübner R; Gölnitz U; Röhle A; Dudesek A; Meyer W; Wittstock M; Mascher H
PLoS One; 2013; 8(11):e79732. PubMed ID: 24278166
[TBL] [Abstract][Full Text] [Related]
33. Glucosylsphingosine Causes Hematological and Visceral Changes in Mice-Evidence for a Pathophysiological Role in Gaucher Disease.
Lukas J; Cozma C; Yang F; Kramp G; Meyer A; Neßlauer AM; Eichler S; Böttcher T; Witt M; Bräuer AU; Kropp P; Rolfs A
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053611
[TBL] [Abstract][Full Text] [Related]
34. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry.
Menkovic I; Boutin M; Alayoubi A; Curado F; Bauer P; Mercier FE; Auray-Blais C
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741225
[TBL] [Abstract][Full Text] [Related]
36. Bone events and evolution of biologic markers in Gaucher disease before and during treatment.
Stirnemann J; Belmatoug N; Vincent C; Fain O; Fantin B; Mentré F
Arthritis Res Ther; 2010; 12(4):R156. PubMed ID: 20696071
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers in Serbian patients with Gaucher disease.
Sumarac Z; Suvajdžić N; Ignjatović S; Majkić-Singh N; Janić D; Petakov M; Dorđević M; Mitrović M; Dajak M; Golubović M; Rodić P
Clin Biochem; 2011 Aug; 44(12):950-4. PubMed ID: 21640089
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach.
Menkovic I; Boutin M; Alayoubi A; Mercier FE; Rivard GÉ; Auray-Blais C
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114153
[TBL] [Abstract][Full Text] [Related]
40. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
